3930. Famotidine

Nomenclature

CAS number: 76824-35-6
3-[[[2-[(Aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)propanimidamide; [1-amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide; N-sulfamoyl-3-[(2-guanidinothiazol-4-yl)methylthio]propionamide; YM-11170; MK-208; Amfamox (Merck & Co.); Fadul (Hexal); Famodil (Sigma-Tau); Famosan (ProMed); Famoxal (Silanes); Ganor (Boehringer, Ing.); Gaster (Yamanouchi); Gastridin (Merck & Co.); Gastropen (Schwarz); Lecedil (Zdravlje); Motiax (Neopharmed); Muclox (Sigma-Tau); Pepcid (Merck & Co.); Pepcidac (McNeil); Pepcidine (Merck & Co.); Pepdine (Merck & Co.); Pepdul (Merck & Co.); Peptan (Merck & Co.); Ulfamid (Krka).
C8H15N7O2S3; mol wt 337.45.
C 28.47%, H 4.48%, N 29.06%, O 9.48%, S 28.51%.

Description and references

Histamine H2-receptor antagonist. Prepn, NMR and mass spectral data: H. Yasufumi et al., BE 882071; eidem, US 4283408; JP Kokai 81 55383, C.A. 95, 203930n (1980, 1981, 1981 all to Yamanouchi). Inhibition of gastric acid and pepsin secretion in rats: M. Takeda et al., Arzneim.-Forsch. 32, 734 (1982); in man: M. Miwa et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 22, 214 (1984). Effect on disposition of antipyrine in liver: Ch. Staiger et al., Arzneim.-Forsch. 34, 1041 (1984). Chromatographic determn in plasma and urine: W. C. Vincek et al., J. Chromatogr. 338, 438 (1985). Clinical trial in Zollinger-Ellison syndrome: J. M. Howard et al., Gastroenterology 88, 1026 (1985). Symposia on pharmacology and clinical efficacy: Am. J. Med. 81, Suppl. 4B, 1-64 (1986); Scand. J. Gastroenterol. 22, Suppl. 134, 1-62 (1987). Tolerability and safety profile: C. W. Howden, G. N. J. Tytgat, Clin. Ther. 18, 36-54 (1996). Review of clinical pharmacokinetics: H. Echizen, T. Ishizaki, Clin. Pharmacokinet. 21, 178-194 (1991).

Chemical structure

Properties

White to pale yellow crystalline compound, mp 163-164°. Soly at 20° (%, w/v): 80 in DMF; 50 in acetic acid; 0.3 in methanol; 0.1 in water; <0.01 in ethanol, ethyl acetate, chloroform. LD50 i.v. in mice: 244.4 mg/kg (Yasufumi).

Therapeutic Category

Antiulcerative.

Therapeutic Category (Veterinary)

Antiulcerative.

Keywords

Antiulcerative; Histamine H2-Receptor Antagonist